Patents by Inventor Raphael Nudelman
Raphael Nudelman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20140235528Abstract: Patients needing NO donor therapy or inhibition of pathologically proliferating cells or increased NO bioactivity are treated with a therapeutically effective amount of an inhibitor of glutathione-dependent formaldehyde dehydrogenase.Type: ApplicationFiled: April 24, 2014Publication date: August 21, 2014Applicant: DUKE UNIVERSITYInventors: Jonathan S. Stamler, Limin Liu, Alfred Hausladen, Raphael Nudelman
-
Patent number: 8759382Abstract: Disclosed are novel derivatives of propargyl-trifluoromethoxy-amino-benzothiazole which are effective in treating neurologic disorders, including Parkinson's disease and multiple sclerosis.Type: GrantFiled: September 29, 2011Date of Patent: June 24, 2014Assignee: Teva Pharmaceutical Industries Ltd.Inventors: Eliezer Falb, Jeffrey Sterling, Yaacov Herzig, Raphael Nudelman, Konstantin Ulanenko
-
Publication number: 20130172364Abstract: Disclosed are novel derivatives of propargyl-trifluoromethoxy-amino-benzothiazole which are effective in treating neurologic disorders, including Parkinson's disease and multiple sclerosis.Type: ApplicationFiled: September 29, 2011Publication date: July 4, 2013Applicant: TEVA PHARMACEUTICAL INDUSTRIES LTD.Inventors: Eliezer Falb, Jeffrey Sterling, Yaacov Herzig, Raphael Nudelman, Konstantin Ulanenko
-
Publication number: 20120245116Abstract: Patients needing NO donor therapy or inhibition of pathologically proliferating cells or increased NO bioactivity are treated with a therapeutically effective amount of an inhibitor of glutathione-dependent formaldehyde dehydrogenase.Type: ApplicationFiled: June 8, 2012Publication date: September 27, 2012Applicant: Duke UniversityInventors: Jonathan S. Stamler, Limin Liu, Alfred Hausladen, Raphael Nudelman
-
Patent number: 8217006Abstract: Patients needing NO donor therapy or inhibition of pathologically proliferating cells or increased NO bioactivity are treated with a therapeutically effective amount of an inhibitor of glutathione-dependent formaldehyde dehydrogenase.Type: GrantFiled: September 24, 2009Date of Patent: July 10, 2012Assignee: Duke UniversityInventors: Jonathan S. Stamler, Limin Liu, Alfred Hausladen, Raphael Nudelman
-
Publication number: 20100015121Abstract: Patients needing NO donor therapy or inhibition of pathologically proliferating cells or increased NO bioactivity are treated with a therapeutically effective amount of an inhibitor of glutathione-dependent formaldehyde dehydrogenase.Type: ApplicationFiled: September 24, 2009Publication date: January 21, 2010Applicant: DUKE UNIVERSITYInventors: Jonathan S. Stamler, Limin Liu, Alfred Hausladen, Raphael Nudelman
-
Patent number: 7615535Abstract: Patients needing NO donor therapy or inhibition of pathologically proliferating cells or increased NO bioactivity are treated with a therapeutically effective amount of an inhibitor of glutathione-dependent formaldehyde dehydrogenase.Type: GrantFiled: December 29, 2006Date of Patent: November 10, 2009Assignee: Duke UniversityInventors: Jonathan S. Stamler, Limin Liu, Alfred Hausladen, Raphael Nudelman
-
Patent number: 7491727Abstract: The invention relates to 5-HT receptor agonists or antagonists. Novel arylpiperazinyl sulfonamide compounds represented by Formula I, and synthesis and uses thereof for treating diseases including those mediated directly or indirectly by 5-HT receptors, are disclosed. Such conditions include central nervous system disorders such as generalized anxiety disorder, ADD/ADHD, neural injury, stroke, and migraine. Methods of preparation and novel intermediates and pharmaceutical salts thereof are also included.Type: GrantFiled: September 5, 2006Date of Patent: February 17, 2009Assignee: Epix Delaware, Inc.Inventors: Dale S. Dhanoa, Dongli Chen, Oren Becker, Silvia Noiman, Srinivasa R. Cheruku, Yael Marantz, Anurag Sharadendu, Sharon Shacham, Alexander Heifetz, Pradyumna Mohanty, Boaz Inbal, Merav Fichman, Raphael Nudelman, Shay Bar-Haim
-
Patent number: 7488731Abstract: The invention relates to 5-HT receptor agonists or antagonists. Novel arylpiperazinyl sulfonamide compounds represented by Formula I, and synthesis and uses thereof for treating diseases including those mediated directly or indirectly by 5-HT receptors, are disclosed. Such conditions include central nervous system disorders such as generalized anxiety disorder, ADD/ADHD, neural injury, stroke, and migraine. Methods of preparation and novel intermediates and pharmaceutical salts thereof are also included.Type: GrantFiled: July 24, 2007Date of Patent: February 10, 2009Assignee: Epix Delaware, Inc.Inventors: Dale S. Dhanoa, Dongli Chen, Oren Becker, Silvia Noiman, Srinivasa R. Cheruku, Yael Marantz, Anurag Sharadendu, Sharon Shacham, Alexander Heifetz, Pradyumna Mohanty, Boaz Inbal, Merav Fichman, Raphael Nudelman, Shay Bar-Haim
-
Publication number: 20080027066Abstract: The invention relates to 5-HT receptor agonists or antagonists. Novel arylpiperazinyl sulfonamide compounds represented by Formula I, and synthesis and uses thereof for treating diseases including those mediated directly or indirectly by 5-HT receptors, are disclosed. Such conditions include central nervous system disorders such as generalized anxiety disorder, ADD/ADHD, neural injury, stroke, and migraine. Methods of preparation and novel intermediates and pharmaceutical salts thereof are also included.Type: ApplicationFiled: July 24, 2007Publication date: January 31, 2008Inventors: Dale Dhanoa, Dongli Chen, Oren Becker, Silvia Noiman, Srinivasa Cheruku, Yael Marantz, Anurag Sharadendu, Sharon Shacham, Alexander Heifetz, Pradyumna Mohanty, Boaz Inbal, Merav Fichman, Raphael Nudelman, Shay Bar-Haim
-
Publication number: 20070111949Abstract: Patients needing NO donor therapy or inhibition of pathologically proliferating cells or increased NO bioactivity are treated with a therapeutically effective amount of an inhibitor of glutathione-dependent formaldehyde dehydrogenase.Type: ApplicationFiled: December 29, 2006Publication date: May 17, 2007Inventors: Jonathan Stamler, Limin Liu, Alfred Hausladen, Raphael Nudelman
-
Patent number: 7179791Abstract: Patients needing NO donor therapy or inhibition of pathologically proliferating cells or increased NO bioactivity are treated with a therapeutically effective amount of an inhibitor of glutathione-dependent formaldehyde dehydrogenase.Type: GrantFiled: January 11, 2001Date of Patent: February 20, 2007Assignee: Duke UniversityInventors: Jonathan S. Stamler, Limin Liu, Alfred Hausladen, Raphael Nudelman
-
Publication number: 20070004742Abstract: The invention relates to 5-HT receptor agonists or antagonists. Novel arylpiperazinyl sulfonamide compounds represented by Formula I, and synthesis and uses thereof for treating diseases including those mediated directly or indirectly by 5-HT receptors, are disclosed. Such conditions include central nervous system disorders such as generalized anxiety disorder, ADD/ADHD, neural injury, stroke, and migraine. Methods of preparation and novel intermediates and pharmaceutical salts thereof are also included.Type: ApplicationFiled: September 5, 2006Publication date: January 4, 2007Inventors: Dale Dhanoa, Dongli Chen, Oren Becker, Silvia Noiman, Srinivasa Cheruku, Yael Marantz, Anurag Sharadendu, Sharon Shachem, Alexander Heifetz, Pradyumna Mohanty, Boaz Inbal, Merav Fichman, Raphael Nudelman, Shay Bar-Haim
-
Patent number: 7153858Abstract: The invention relates to 5-HT receptor agonists or antagonists. Novel arylpiperazinyl sulfonamide compounds represented by Formulae I: and II, and synthesis and uses of those compounds for treating diseases including those mediated directly or indirectly by 5-HT receptors, are disclosed. Such conditions include central nervous system disorders such as generalized anxiety disorder, ADD/ADHD, neural injury, stroke, and migraine. Methods of preparation and novel intermediates and pharmaceutical salts thereof are also included.Type: GrantFiled: January 30, 2004Date of Patent: December 26, 2006Assignee: Epix Delaware, Inc.Inventors: Dale S. Dhanoa, Dongli Chen, Oren Becker, Silvia Noiman, Srinivasa Rao Cheruku, Yael Marantz, Anurag Sharadendu, Sharon Shachem, Alexander Heifetz, Pradyumna Mohanty, Boaz Inbal, Merav Fichman, Raphael Nudelman, Shay Bar-Haim
-
Publication number: 20040220192Abstract: The invention relates to 5-HT receptor agonists or antagonists. Novel arylpiperazinyl sulfonamide compounds represented by Formula I, and synthesis and uses thereof for treating diseases including those mediated directly or indirectly by 5-HT receptors, are disclosed. Such conditions include central nervous system disorders such as generalized anxiety disorder, ADD/ADHD, neural injury, stroke, and migraine. Methods of preparation and novel intermediates and pharmaceutical salts thereof are also included.Type: ApplicationFiled: January 30, 2004Publication date: November 4, 2004Inventors: Dale S. Dhanoa, Dongli Chen, Oren Becker, Silvia Noiman, Srinivasa Rao Cheruku, Yael Marantz, Anurag Sharadendu, Sharon Shachem, Alexander Heifetz, Pradyumna Mohanty, Boaz Inbal, Merav Fichman, Raphael Nudelman, Shay Bar-Haim
-
Publication number: 20040138238Abstract: The invention discloses tachykinin receptor antagonists. The tachykinin family of receptors comprising the neurokinins substance P (SP), neurokinin A, and neurokinin B and related neuropeptides that are widely distributed in the peripheral and central nervous system. The invention discloses novel aminopyrimidine derivatives, synthesis and uses thereof for the treatment of diseases mediated directly or indirectly by the tachykinin receptors. These diseases include central nervous system disorders such as anxiety, pain, depression, emesis, in particular cancer chemotherapy induced emesis, respiratory and inflammatory bowel disease and other gastric disorders, asthma, schizophrenia, ophthalmic diseases such as glaucoma, ocular hypotension, neural injury, stroke, cardiac disorders, psoriasis, and migraine. Methods of preparation and novel intermediates and pharmaceutical salts thereof are also included.Type: ApplicationFiled: July 24, 2003Publication date: July 15, 2004Inventors: Dale S. Dhanoa, Oren Becker, Silvia Noiman, Venkitasamy Kesavan, Anurag Sharadendu, Pradyumna Mohanty, Dongli Chen, Srinivasa Rao Cheruku, Alexander Heifetz, Ori Kalid, Yael Marantz, Raphael Nudelman, Sharon Sbacham, Shay Bar-Haim
-
Publication number: 20020128205Abstract: Patients needing NO donor therapy or inhibition of pathologically proliferating cells or increased NO bioactivity are treated with a therapeutically effective amount of an inhibitor of glutathione-dependent formaldehyde dehydrogenase.Type: ApplicationFiled: January 11, 2001Publication date: September 12, 2002Applicant: DUKE UNIVERSITY Office of Science and TechnologyInventors: Jonathan S. Stamler, Limin Liu, Alfred Hausladen, Raphael Nudelman
-
Patent number: 5486591Abstract: A monomeric diacid derivative includes at least two fatty acids coupled by hydrolytically or enzymatically degradable bond. In a biological environment, the bond degrades forming naturally occurring fatty acid products thereby allowing elimination.Type: GrantFiled: March 21, 1995Date of Patent: January 23, 1996Assignee: Yissum Research Development Co. of the Hebrew University of JerusalemInventors: Abraham J. Domb, Raphael Nudelman
-
Patent number: 5473103Abstract: A monomeric diacid derivative includes at least two fatty acids coupled by a hydrolytically or enzymatically degradable bond. In a biological environment, the bond degrades forming naturally occurring fatty acid products thereby allowing elimination.Type: GrantFiled: December 16, 1993Date of Patent: December 5, 1995Assignee: Yissum Research Development Co. of the Hebrew University of JerusalemInventors: Abraham J. Domb, Raphael Nudelman